WELCOME TO

Copenhagen economics

who are we?

Copenhagen Economics is an international, expert-driven consulting firm built on a deep knowledge of applied economics. We believe that sound economic analysis, coupled with clear communication of the results, equips decision makers with the Hard Facts and Clear Stories to make superior decisions for the benefit of society.

Economics experts in Healthcare & Life Sciences

One of our flagship services is Healthcare & Life Sciences, headed by our Partner Julia Wahl. As respected experts in the healthcare and life sciences area, we have vast experience in a range of orphan drug issues. We help companies and governments transform the most complex parts of policy, market-shaping strategies, and conflict cases into actionable steps.

For more information on what we do, download the material on the right or reach out to us directly.

learn more about how we can help

download

Cases

  • Can HARD FACTS deliver clear skies to any given forecast?

    We help international pharmaceutical companies assess the impact of potential changes to the Orphan Medicinal Product (OMP) Regulation on their portfolio of orphan drugs.

    This enables our clients to improve their understanding of the impact on revenue, align internally on a common view and position, and steer their public advocacy efforts towards the proposals with the most favourable impacts. Read more.

  • Can your CLEAR STORIES make the EU Commission think twice?

    We are a knowledge partner with the European Expert Group on Orphan Drug Incentives (OD Expert Group), providing insights that facilitate this multi-stakeholder group's work, and helping them design a new policy framework for orphan drugs in Europe.

    Our work with the OD Expert Group has resulted in the identification of four main needs and fourteen policy proposals that we co-presented with DG Sante to the European Parliament. Read more.

  • Do new policies give you a headache?

    Our work with an international pharmaceutical company demonstrated the societal value of a innovative, preventive treatment of severe migraine through the use of CGRP inhibitors using of real-world evidence (RWE).

    We showed this using a tailored economic model to monetise the value and patient-reported real-world data (RWD). Read more.

  • Browse our work

    Engaging Copenhagen Economics ensures fact-based and precise economic arguments when you are preparing for important strategic decisions, whether that be working to reform regulatory impediments, engaging in legal conflicts, or aiming to communicate your economic value to stakeholders.

    We assist law firms, private companies, regulators, and policymakers all over the world, and every year, our experts produce over 100 publications based on established research methods, cutting-edge data-processing techniques, and in-depth sector knowledge. Read more.

can you turn trust into antitrust?

Make a note in your calendar and meet us next year at the EU Pharmaceutical Law Forum 2025, where we will focus on showing you how to turn antitrust into trust.

To find out more before the event, please reach out to Copenhagen Economics Partner Julia Wahl or Service Leader Nikolaj Siersbæk.

Contact us